Cannabis in Peru
Medical OnlyOverview
Peru legalized medical cannabis in 2017 through Law 30681, which authorized the production, importation, and commercialization of cannabis and its derivatives for medicinal and therapeutic purposes. The implementing regulations were published in 2019, establishing a framework for licensing and oversight by DIGEMID (the General Directorate of Medicines, Supplies, and Drugs).
The Peruvian medical cannabis market has developed slowly compared to neighboring Colombia and Chile. Licensing and regulatory implementation have been hampered by bureaucratic challenges and limited government resources. A small number of companies have obtained licenses for cannabis production, and import pathways have been established for cannabis-based medicines. Patient access remains limited but growing, with cannabis oils being the most common product form.
Peru's traditional relationship with coca cultivation and its complex drug policy history create a unique context for cannabis reform. The country's approach has been cautious, reflecting a desire to balance patient access with concerns about illicit market dynamics. Personal use of cannabis remains subject to criminal penalties, though enforcement varies.
Despite the slow pace of implementation, Peru's agricultural conditions and labor costs could support competitive cannabis production if the regulatory framework matures. Several international companies have explored Peruvian operations, though most remain in early development stages. The country's 34 million population represents a meaningful potential domestic market as well.
Key Facts
- Medical cannabis legalized in 2017 through Law 30681
- DIGEMID oversees licensing and regulatory compliance
- Implementation has been slower than in neighboring countries
- Cannabis oils are the most common product form
- Personal use remains subject to criminal penalties
- Agricultural conditions could support competitive production
Recent Developments
Regulatory framework gradually being refined and streamlined
Number of licensed medical cannabis operations slowly growing
Import pathways for cannabis medicines being utilized
Patient advocacy organizations increasing visibility
Investment Implications
Peru is an early-stage cannabis market with limited near-term investment opportunities. The slow regulatory pace and political uncertainty create high barriers to entry. However, the country's agricultural potential and population base suggest long-term opportunity if the regulatory environment matures. Investors interested in Latin American cannabis should prioritize more developed markets like Colombia and Brazil while monitoring Peru's progress.